Agomab Therapeutics (AGMB) General Counsel lists sizeable option positions
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Agomab Therapeutics NV General Counsel Ellen Lefever filed an initial statement of beneficial ownership, detailing several stock option awards over common shares. These options give rights to buy AGMB shares at exercise prices including $2.7600, $3.1800 and $14.2600, with expirations from 2031 through 2036.
One grant covers 91,256 underlying common shares at $2.7600 per share expiring on March 5, 2031, and another covers 127,972 shares at $14.2600 expiring on January 15, 2036, all held directly. Footnotes note that some options are fully vested while others vest over time, that common shares may be represented by ADSs on a 1:1 basis, and that exercise prices are reported in U.S. dollars using a stated EUR/USD exchange rate.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Lefever Ellen
Role
General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 91,256 shares (Direct)
Footnotes (1)
- The shares underlying this option are fully vested and exercisable. The common shares may be represented by American Depositary Shares, each of which currently represents one common share. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
FAQ
What does the Agomab Therapeutics (AGMB) Form 3 for Ellen Lefever report?
The Form 3 reports initial beneficial ownership of several stock option awards over Agomab common shares. It lists each grant’s exercise price, expiration date, vesting status, and that the options are held directly by the General Counsel.
What are the exercise prices of the stock options reported by Agomab’s General Counsel?
The options have exercise prices of $2.7600, $3.1800 and $14.2600 per common share. Footnotes state these prices are reported in U.S. dollars, converted from euros using a specified EUR/USD exchange rate as of March 16, 2026.
When do Ellen Lefever’s reported Agomab (AGMB) stock options expire?
The reported stock options expire between March 5, 2031 and January 15, 2036. Each grant lists a specific expiration date, showing the long-dated nature of these awards and the time window during which they may be exercised.
Are the Agomab stock options held by Ellen Lefever vested according to the Form 3?
One option grant is described as fully vested and exercisable. Other grants vest over time, including schedules where 50% vests on February 9, 2026 or 25% on February 9, 2027, with remaining portions vesting in equal monthly installments subject to continued service.